scholarly journals Baseline characteristics and survival outcomes of advanced gastric cancer patients treated with two or more lines of chemotherapy: results from a large Italian cohort

2015 ◽  
Vol 26 ◽  
pp. vi92
Author(s):  
L. Ferrari ◽  
C. Fontanella ◽  
M. Uccello ◽  
G. Pasquini ◽  
S. Bozzarelli ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Survival Outcomes ◽  
Baseline Characteristics ◽  
Gastric Cancer Patients ◽  
Italian Cohort

scholarly journals DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy

2017 ◽  
Vol 140 (11) ◽  
pp. 2587-2595 ◽  
Author(s):  
Livia Ronchetti ◽  
Elisa Melucci ◽  
Francesca De Nicola ◽  
Frauke Goeman ◽  
Beatrice Casini ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Dna Damage ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Dna Damage Repair ◽  
Survival Outcomes ◽  
First Line ◽  
Damage Repair ◽  
Gastric Cancer Patients ◽  
Line Chemotherapy

Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study

2019 ◽  
Author(s):  
Ken Demachi ◽  
Hideaki Bando ◽  
Hisanaga Nomura ◽  
Kohei Shitara ◽  
Takayuki Yoshino ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Renal Function ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Impaired Renal Function ◽  
Safety And Efficacy ◽  
Oxaliplatin Treatment ◽  
Impaired Group ◽  
Baseline Characteristics ◽  
Gastric Cancer Patients

Abstract Backgrounds S-1 plus oxaliplatin appears effective in chemo-naïve patients with advanced gastric cancer. However, comprehensive safety and efficacy data for S-1 plus oxaliplatin is limited for patients with impaired renal function. Methods We retrospectively extracted data from advanced gastric cancer patients with normal renal function (normal group, CLcr ≥ 60 ml/min), who were treated with standard doses of S-1 (80 mg/m2) plus oxaliplatin (100 mg/m2), and patients with impaired renal function (impaired group, CLcr < 60 ml/min) who were treated with standard or reduced doses of S-1 (60 mg/m2 or 40 mg/m2) plus standard doses of oxaliplatin. Treatment efficacy and safety between the groups were compared. Results Data from 100 normal patients and 42 patients with impaired renal function were extracted. Baseline characteristics differed significantly between the two groups, including age (median, 64 vs 72 years, P < 0.0001) and body surface area (median, 1.68 vs 1.51 m2, P < 0.0001). In the impaired group, 66.6% (28/42) started with a reduced dose. Within the impaired group, more patients had a reduced initial S-1 dose when CLcr <50 ml/min (77.3%). The median progression-free and overall survival between the normal and impaired groups was 6.1 vs 5.7 months (P = 0.698) and 16.1 vs 18.5 months (P = 0.638), respectively. Conclusions S-1 plus oxaliplatin in advanced gastric cancer patients with impaired renal function appears safe and has demonstrated efficacy given appropriate dose modification.

Sign in / Sign up

Export Citation Format

Share Document